Abstract:
Kudo Biotechnology is a global mRNA CDMO company headquartered in Singapore, providing world-class end-to-end cGMP manufacturing solutions for your mRNA needs. Kudo streamlines the manufacturing process of plasmid DNA, mRNA, lipid nanoparticle (LNP) and fill/finish, removing bottlenecks and ensuring ease in your CMC needs. Kudo has a state-of-the-art cGMP manufacturing facility and MSAT laboratories in Shanghai, and a process & analytical development center in Needham, MA. Join Kudo Biotechnology on December 06, 2023 to gain insights into Kudo’s comprehensive solutions for our clients’ drug development needs.
In this webinar, we will present a case study on a clinical batch supply for our client. We will discuss in detail on how Kudo shortened the resupply production timeline by six months. In addition, we will share how Kudo helped the client find alternative suppliers for high value raw materials to reduce future program’s production cost by 68% without impacting the product quality. The speaker will also go over Kudo’s capabilities and our globalized facilities with services for process development, analytical development and GMP manufacturing.
Time:
1:00pm EST (10am PST), Dec 6, 2023
Speaker:
Speaker name: Atsuko Sangria, PhD
Title: Director, Drug Substance Process Development
Organization: Kudo Biotechnology
Biography
Atsuko Sakurai-Sangria, Ph.D. is the Director of Drug Substance Process Development. Atsuko has 16 years of research experience in molecular biology and vaccine development. Prior to joining Kudo Bio, Atsuko led the mRNA drug substance (DS) process development, scale-up, and technology transfer at RVAC Medicines, a mRNA product company. Previously to RVAC Medicines, Atsuko was an expert scientist at GSK Vaccines, where she played a vital role in mRNA vaccine platform development. She also has preclinical and process development experience in biological products from her past role at VLP Therapeutics and postdoctoral training in the National Institute of Health. Atsuko obtained her Ph.D. in Pharmaceutical Sciences from Kitasato University in Japan.
Speaker name: Kelvin Chan, PhD
Title: Director, Business Development
Organization: Kudo Biotechnology
Biography
Kelvin Chan, PhD, is the Director of Business Development at Kudo Bio. Kelvin is a globally experienced healthcare investor-operator and was formerly Director of Business Development at ABio-X, a CBC Group biotech incubator, as well as Director of Business Development at RVAC Medicines, a mRNA product company. Previously, Kelvin was an operator of several portfolio companies at Tavistock Group. He was formerly a cross-border venture capital investor with EDBI, the strategic investment arm of the Singapore Economic Development Board, investing broadly across healthcare and life sciences. Kelvin holds a PhD in Organic Chemistry from Scripps Research, and conducted his postdoc at the Singapore Bioimaging Consortium. He received his BA (Hons) in Chemistry with First Class Honors at the University of Cambridge, UK. Kelvin is a recipient of the prestigious National Science Scholarship from A*STAR Singapore.
Related services:
GMP mRNA & LNP
End-to-end Solution Provider for mRNA-LNP
READ MORE
mRNA cGMP Manufacturing by Kudo
READ MORE
Research mRNA & LNP service
Accelerating your vaccine and drug development from discovery to production
READ MORE
